TEMPE, Ariz.–(BUSINESS WIRE)–iMetabolic Biopharma Corporation (iMBP) announces expansion of its strategic partnership relationship with Ligand Pharmaceuticals, building on an earlier alliance agreement initiated in 2018, giving access to Ligand’s OmniAb platform. Continue reading
Category Archives: AZBio News
C-Path and Diamyd Medical Announce Data Sharing Collaboration to Develop Advanced Drug Development Tools in Type 1 Diabetes
TUCSON, Ariz., and STOCKHOLM, Sweden. December 16, 2020 — The Critical Path Institute (C-Path) and Diamyd Medical (DMYD B; Nasdaq First North Growth Market) are proud to announce their collaboration to significantly improve the scientific community’s insight into type 1 diabetes (T1D) through Diamyd Medical’s contribution of fully anonymized data from a European Phase III trial to the Trial Outcome Markers Initiative (TOMI-T1D) integrated database. The Phase III trial evaluated the use of the diabetes vaccine Diamyd®, an antigen-specific immunotherapy based on the auto-antigen GAD (glutamic acid decarboxylase), to induce immunological tolerance and stop the autoimmune destruction of insulin producing cells. The Data Contribution Agreement (DCA) between Diamyd Medical and C-Path will allow for this unique set of fully anonymized clinical trial data to be integrated into an ever-growing list of committed trial data sets within the TOMI-T1D project.Continue reading
AZBio Career Center Launches Expanded Career Planning Portal
The Career Planning Portal by YM Careers®, a component of the AZBio Career Center that allows AZBio Members to create an account and access tools for researching, planning and developing their careers for years to come!Continue reading
Rockefeller Foundation’s third National Covid-19 Testing Action Plan calls on the U.S. government to massively scale up Covid-19 testing
Rockefeller Foundation’s third National Covid-19 Testing Action Plan calls on the U.S. government to massively scale up Covid-19 testing an lays out a new plan for the largest domestic testing scale up to date and proposes 14 executive actions for the current and incoming administrations to take in order to rapidly alter the trajectory of the pandemic in the United States. Testing all U.S. public K-12 public schools would cost $42.5 billion, or $8.5 billion per month for the remainder of the school year from February to June 2021.Continue reading
Opportunity Alert – Applications for TGen’s Summer Program are Now Open
Helios Scholars at TGen offers students full-time, paid internship opportunities that include research experience and professional development in the field of biomedical research.Continue reading
Pfizer and BioNTech Celebrate Historic First Authorization in the U.S. of Vaccine to Prevent COVID-19
- U.S. FDA authorizes COVID-19 mRNA vaccine for emergency use; companies are prepared to deliver first doses in the U.S. immediately
- Pfizer and BioNTech previously announced an agreement with the U.S. Government to supply doses in 2020 & 2021
In collaboration with Operation Warp Speed, Pfizer and BioNTech, as well as other vaccine companies are expected to deliver hundreds of millions of vaccine doses to Americans by the end of 2021 - Historic science-driven efforts will seek to help bring an end to the most devastating pandemic in a century
- Pfizer and BioNTech expect to file a Biologics License Application for possible full regulatory approval in 2021
AZBio Celebrates Trailblazers in 2020
Each year, AZBio looks back across the legislative session to identify those leaders whose actions and active engagement support the growth of Arizona’s life science and healthcare industry and help to ensure the people of Arizona benefit from its success. Scores are then tallied and the top ten legislative leaders are named the year’s Trailblazers.Continue reading
NIH’s All of Us Research Program returns first genetic results to participants
The All of Us Research Program offers participants the opportunity to receive information back about their DNA. NIH
The National Institutes of Health’s All of Us Research Program has begun to return genetic results to participants who have donated biosamples for research. This reflects the program’s priority to give back information to its research volunteers. Initially, participants can choose to receive information about their genetic ancestry and traits, with health-related results available at a later date.Continue reading
HTG Announces an Early Access Program for its Prototype Whole Transcriptome Panel
TUCSON, Ariz., Dec. 08, 2020 (GLOBE NEWSWIRE) — HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today announced that it has launched an Early Access Program for its whole transcriptome panel using the HTG EdgeSeq technology. The Early Access Program is intended to allow select customers access to the panel in their laboratories or through services to be performed in our development laboratory prior to commercial launch of this product.Continue reading